• COMPANY

    Olink Bioscience develops procedures, products, and services for protein and nucleic acid analysis and for diagnostics particularly with applications in the field of in situ protein detection and DNA/RNA based blood tests.

    Contact: info@olinkbioscience.com

    Detection of PPIs and PTMs in cells and tissue – Product in development

    Signal transduction through PPIs, and PTMs, plays a fundamental role in many biological processes. Correct visualization of protein-interactions is a key to understand many diseases, such as neurodegenerative diseases and cancer, and essential during the development of many new therapies and diagnostic tests.

    We are at present finalizing the development of an Olink Bioscience product line for visualization of PPIs and PTMs. This product will have an important role for research on PPI and PTM targets as well as in drug development or as a diagnostic tests to identify and distinguish forms of disease or reflect responses by patients to therapies. Olink Bioscience will release a General Purpose RUO kit and specific Biomarker Assay products based on our proprietary ProxHCR technology. Two examples are presented below, further information under Technology.

    (Left) Mesothelin (MSLN) is a tumor differentiation antigen highly expressed in mesotheliomas and ovarian cancers. Secreted MSLN is capable of binding to CA125, one of the most commonly used serum marker for several types of cancer. CA125 is secreted from the tumor into the peritoneal cavity and binds to MSLN present on mesothelial cells. CA125 is also expressed on circulating tumor cells and the interaction between MSLN and CA125 promotes metastasis.
    (Right) Cadherin/Catenin-based anchoring junctions, organize and bind microfilaments to maintain cell adhesive properties and integrate intra- and intercellular signaling, including regulation of nuclear functions and transcription pathways.

    DNA/RNA BASED BLOOD TESTS

    The Company also develops a blood based tests utilizing a unique technology that enables us to digitally count and analyze specific cell-free DNA (cfDNA) sequences for screening or diagnostic purposes.